Organization | US WorldMeds

US WorldMeds Report issue

Contributed to NME For profit Phase 1 Phase 4

Founded: Louisville KY United States (2001)

Status: No NME R&D (2001)

Organization Overview

First Clinical Trial

2006

NCT00235729

First Marketed Drug

2001

nadolol (corgard)

First NDA Approval

2018

lofexidine (lucemyra)

Last Known Activity

2023

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Marketed Drugs (8)

apomorphine (apokyn) (2004)

dantrolene (dantrium) (2007)

eflornithine (ornidyl) (2023)

lofexidine (lucemyra) (2018 NDA)

melphalan (alkeran) (2019)

nadolol (corgard) (1979)

safinamide (xadago) (2017)

tegaserod (zelnorm) (2002)

Drugs in Phase 4 Trials (5)

Key: US WorldMeds (4) Acquired (1)

apomorphine (apokyn) (3 trials)

levodopa (larodopa) (1 trial)

lofexidine (lucemyra) (20 trials)

rimabotulinumtoxinB (Myobloc) (8 trials)

trimethobenzamide (tigan) (1 trial)

Drugs in Phase 1 Trials (3)

buprenorphine (1 trial)

naltrexone (revia) (1 trial)

paroxetine (paxil) (1 trial)

Indications

Approved Indications

Opioid-Related Disorders

Experimental Indications (Clinical Trials, Phases 1-4)

Behavior, Addictive (Phase 3)

Disease (Phase 2)

Liver Failure (Phase 1)

Muscle Spasticity (Phase 3)

Opioid-Related Disorders (Phase 3)

Parkinson Disease (Phase 4)

Sialorrhea (Phase 3)

Stress Disorders, Post-Traumatic (Phase 2)

Stress Disorders, Traumatic (Phase 2)

Substance-Related Disorders (Phase 2)

Substance Withdrawal Syndrome (Phase 3)

Syndrome (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 31
# of Trial APIs: 8